Enveric Biosciences (NASDAQ:ENVB) Releases Quarterly Earnings Results, Beats Estimates By $0.30 EPS

Enveric Biosciences (NASDAQ:ENVB) posted its quarterly earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.30, Yahoo Finance reports.

Enveric Biosciences Stock Down 7.8 %

Enveric Biosciences stock traded down $0.04 during trading hours on Wednesday, hitting $0.49. The stock had a trading volume of 162,555 shares, compared to its average volume of 2,381,886. The stock’s 50-day moving average price is $0.58 and its 200-day moving average price is $0.83. The stock has a market capitalization of $3.90 million, a P/E ratio of -0.08 and a beta of 0.74. Enveric Biosciences has a 12-month low of $0.41 and a 12-month high of $2.92.

About Enveric Biosciences

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.